| Title: | From blood to breath: New horizons for esophageal cancer biomarkers |
| Author(s): | Yazbeck R; Jaenisch SE; Watson DI; |
| Address: | "Roger Yazbeck, Simone E Jaenisch, David I Watson, Department of Surgery, Flinders Centre for Innovation in Cancer, Flinders University, South Australia 5042, Australia" |
| DOI: | 10.3748/wjg.v22.i46.10077 |
| ISSN/ISBN: | 2219-2840 (Electronic) 1007-9327 (Print) 1007-9327 (Linking) |
| Abstract: | "Esophageal cancer is a lethal cancer encompassing adenocarcinoma and squamous cell carcinoma sub-types. The global incidence of esophageal cancer is increasing world-wide, associated with the increased prevalence of associated risk factors. The asymptomatic nature of disease often leads to late diagnosis and five-year survival rates of less than 15%. Current diagnostic tools are restricted to invasive and costly endoscopy and biopsy for histopathology. Minimally and non-invasive biomarkers of esophageal cancer are needed to facilitate earlier detection and better clinical management of patients. This paper summarises recent insights into the development and clinical validation of esophageal cancer biomarkers, focussing on circulating markers in the blood, and the emerging area of breath and odorant biomarkers" |
| Keywords: | "Adenocarcinoma/diagnosis/*metabolism Autoantibodies/*metabolism Biomarkers, Tumor/*metabolism Breath Tests Carcinoembryonic Antigen/metabolism Carcinoma, Squamous Cell/diagnosis/*metabolism Esophageal Neoplasms/diagnosis/*metabolism Esophageal Squamous Ce;" |
| Notes: | "MedlineYazbeck, Roger Jaenisch, Simone E Watson, David I eng Editorial Review 2016/12/29 World J Gastroenterol. 2016 Dec 14; 22(46):10077-10083. doi: 10.3748/wjg.v22.i46.10077" |
